Labcorp Holdings
✦ Quant Fair Value how this is computed
- Implied fair-value range of 151.27-377.89, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is +38.8% above the average-multiple fair value of 264.58.
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Labcorp Holdings (LH) | 29.81B | 30.09 | 3.37 | 0.78% |
| Thermo Fisher Scientific (TMO) | 248.08B | 35.31 | 4.53 | 0.27% |
| Danaher (DHR) | 155.03B | 36.12 | 2.89 | 0.69% |
| IDEXX Laboratories Inc (IDXX) | 53.28B | 45.57 | 28.50 | 0.00% |
| Agilent Technologies (A) | 48.04B | 33.61 | 6.52 | 0.59% |
| Waters (WAT) | 43.29B | 184.29 | 2.83 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 5.5% above Morningstar's fair value estimate.
Analyst note
Labcorp posted third-quarter performance that included revenue and adjusted earnings per share growth of 7% and 15%, respectively. Shares traded up 9% on the news.
Why it matters: Labcorp has delivered its 10th consecutive quarter of mid-single- to high-single-digit revenue growth, primarily reflecting the larger trend toward higher medical utilization starting in 2024. However, the prospect of PAMA and shrinking insureds could be challenging in 2027. As with the competitive set, Labcorp is well-positioned to benefit as new screening guidelines for cardiovascular and, especially, for monitoring women’s heart health through life stages have been recently released. We expect stronger demand in the fourth quarter, as many insureds have met their deductibles and those planning to drop coverage in 2027 may try to front-load their healthcare spending before Jan. 1.
The bottom line: We’ve raised our fair value estimate to $347 per share from $293, after adjusting our projections for the latest outperformance and incorporating our new cost of capital methodology that lowered the discount rate by roughly 60 basis points. We remain confident in Labcorp’s narrow moat, too. We continue to hold moderate expectations for 4% annual top-line growth during 2027-30, along with 250 basis points of improvement in operating margin by 2030, supported by test mix and lab efficiencies. With the prospect of PAMA implementation looming, we’ve incorporated a 50% probability of this event in our model. Congress still has an even chance of postponing the next round of PAMA, as it has done six times before.
Big picture: Our main concern is that medical utilization could soften next year as new policies cut into the Medicaid population and related spending, which would be a headwind for the labs.
Fair value
We’ve increased our fair value estimate to $347 per share, up from $293, to reflect the firm's recent strength and our expectation for robust fourth-quarter results. We hold moderate estimates for 2027 through 2030 and assume ongoing cost-containment measures, test menu expansion, and topspin from the acquisition of hospital outreach programs and smaller labs translate into consolidated average annual revenue growth of 4%. We have also incorporated our new cost of capital methodology, which lowered the discount rate by 60 basis points.
We anticipate demand for covid molecular tests will fall to nonmaterial levels in winter 2026-27, similar to that of seasonal flu. We currently think there is a 50/50 chance that the PAMA-led cuts to the Medicare clinical lab fee schedule will be implemented in 2027. Unshackled from the lower-margin CRO segment, we anticipate Labcorp can improve its operating margin by roughly 250 basis points in 2030.
In keeping with the longer-term trend, we anticipate faster growth in genomic and esoteric testing than in routine testing. Labcorp has done a good job of launching new complex tests, which leads us to believe that annual esoteric test volume should outpace market growth. We also think these specialized tests will carry a higher price tag than routine counterparts, resulting in an average annual price increase of about 1% over the long term. This will be offset by the reimbursement pressure on routine tests, which still make up the bulk of Labcorp's test mix by volume. We think some of Labcorp's investments in self-administered specimen collection and new artificial intelligence-enhanced robotic phlebotomy put the firm in a strong position to take advantage of emerging opportunities over the longer term.
Economic moat
Labcorp’s narrow moat is based on its vast national infrastructure in its core diagnostics lab business, which translates into a considerable cost advantage over smaller regional labs in the independent reference lab industry, as well as hospital-based labs. With 34 primary and specialty testing labs and roughly 2,200 patient-service centers across the United States, Labcorp is able to run over 2 million tests each day at a substantially lower cost than most of the hospitals, doctors' offices, and smaller independent labs that populate the market. Labcorp and its main rival, Quest Diagnostics, account for approximately 25% of the US reference lab industry. The rest of the market is highly fragmented, with many small independent labs and hospital-based labs.
Labcorp's ability to accommodate higher throughput and its extensive use of automation affords the firm a much lower cost structure—significantly lower than that of hospitals and smaller independent labs. This advantage also means Labcorp’s model is characterized by substantial operating leverage. This operating leverage has worked against the firm in the wake of the Great Recession when healthcare utilization fell. However, as we saw over the covid-19 pandemic, the sharp acceleration in lab utilization also drove up profitability significantly.
Although we had seen more aggressive price competition between Labcorp and Quest Diagnostics in the early 2000s, pricing has remained rational over the last 20 years and is even less likely to become irrational now that payers have shifted to adopt payment reforms. We think this reflects the influence of value-based healthcare reform, in the wake of the Affordable Care Act. It has become more economically attractive for payers to encourage patients to use any low-cost producer (in place of the more expensive hospital-based labs) instead of pitting Labcorp and Quest against each other to eke out savings that also reduce patient access to lower-cost tests.
Payers prefer to negotiate with the largest reference labs, including Labcorp, that provide the best geographic coverage for the insured base, instead of cobbling together market-by-market coverage through multiple, smaller regional and local labs. In a departure from the exclusive agreements that used to characterize contracts with private payers, the larger managed care organizations have begun shifting to a different model that allows for both of the lowest-cost producers, Labcorp and Quest, to be in-network labs, with the intent of diverting test volume away from the higher-cost hospital-based labs.
Finally, Labcorp's scale and reach make it an attractive partner for researchers who invent various diagnostic tests but have no distribution channels through which to sell the tests. Labcorp has invested in a dedicated lab focused on companion diagnostics and has begun offering liquid biopsy technology for minimal residual disease in oncology patients. We view this as another indication that the firm is thinking more creatively about how to work more closely with other entities in the healthcare arena to stay on top of emerging diagnostic trends.
We don’t think Labcorp's biopharma lab services segment has dug a moat, as it does not compete in the moatier late-stage clinical trials where trial design and regulatory expertise can translate into intangible assets that foster sticky client relationships. In contrast, Labcorp’s BLS business is mainly focused on preclinical and early-stage toxicology studies where trial design isn’t critical. Further, the BLS segment also includes central labs, which is where diagnostic tests from later-stage trials designed and conducted by other contract research organizations are processed. This business is about volume, and Labcorp’s central labs do not offer any distinctive, defensible advantage over any competitive central labs.
From an environmental, social, and governance perspective, Sustainalytics pegs Labcorp's risk on the low end of the medium range, and we concur. ESG risk that could affect the moats for the largest independent diagnostic reference labs is generally low. Some of the most vulnerable areas of risk would include the high quality standards that labs must follow to ensure results are accurate and valid, as well as the possibility of getting caught up in Medicare fraud through incorrect or overbilling.
As we saw with the Theranos debacle, inaccurate test results can lead to inappropriate medical treatment. However, Labcorp has robust, well-established processes in place to lower risk in both quality and billing. This contrasts with smaller independent labs, which have been more likely to stumble in these areas.
Bull case
There is new bipartisan legislation proposed, the Results Act, which would create a less onerous and more representative method to collect the private-payer reimbursement data to help set Medicare payment rates.
The more complex and labor-intensive esoteric tests are reimbursed at a higher rate and often outsourced by hospitals to independent labs such as Labcorp.
Labcorp has been able to keep less profitable capitated managed care contracts to a minimum, accounting for only 3.6% of 2024 diagnostic revenue.
Bear case
CMS has indicated that significant numbers of hospital-based labs did not comply with Medicare's payment reporting requirements for PAMA, which could increase reimbursement pressure after 2026.
The expectation for smaller independent and hospital-based labs to fold under increasing reimbursement pressure has taken longer than anticipated to come to fruition.
If healthcare utilization and test volume soften, Labcorp's profitability could see accelerated declines.
By Debbie S. Wang
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Labcorp Holdings discussion 0 comments